Skip to main content

Pipeline

Product Candidate
Discovery
Preclinical
PHASE 1
PHASE 2
PHASE 3
MARKET
Status
HCVProtease Inhibitor
glecaprevir-containing pan-genotypic 2-DAA combo
Marketed by AbbVie
RSVN-Protein Inhibitor
EDP-938
Phase 2b RSVP study ongoing
NASHFXR Agonist
EDP-305
Phase 2b ARGON-2 study ongoing
HBVCore Inhibitor
EDP-514
Two Phase 1b studies in HBV patients ongoing
NASHFXR Agonist Follow-on
EDP-297
Phase 1 study ongoing
hMPV Non-Fusion Inhibitor
Discovery
COVID-19 SARS-CoV-2 Inhibitor
Discovery
RSV, HBV, NASH, other
Discovery or Preclinical

*Fixed-dose combination contains glecaprevir and AbbVie's NS5A inhibitor, pibrentasvir. Marketed as MAVYRET (U.S.) and MAVIRET (ex-U.S.), it replaces VIEKIRA PAK (no longer sold in the U.S.) and VIEKIRAX (sold primarily in select jurisdictions where MAVIRET is not yet approved).